SEC Form 4 · accession 0000899243-19-006453

Clovis Oncology, Inc. · CLVS

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — See Remarks

Period of report

Mar 5, 2019

Accepted (ET)

Mar 6, 2019 · 4:45 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001466301

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock^F1	Mar 5, 2019	M	625	—	A	16,497	D
Common Stock^F2	Mar 5, 2019	S	321	$29.29	D	16,176	D
Common Stock^F1	Mar 5, 2019	M	2,750	—	A	18,926	D
Common Stock^F2	Mar 5, 2019	S	1,410	$29.29	D	17,516	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Restricted Stock Units^F1,F3	—	Mar 5, 2019	M	625	D	—	—	Common Stock	625	5,000	D
Restricted Stock Units^F1,F4	—	Mar 5, 2019	M	2,750	D	—	—	Common Stock	2,750	8,250	D

F1Each Restricted Stock Unit represents the right to receive one share of Common Stock.
F2Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person.
F3On March 27, 2017, the reporting person was granted 10,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on March 1, 2018, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.
F4On March 1, 2018 , the reporting person was granted 11,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on March 1, 2019, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.

Chief Medical Officer and Executive Vice President of Clinical and Preclinical Development and Pharmacovigilance